FindTrial
Sign In

L-OHP

DRUG3 trials

Sponsors

Osaka Medical College Hospital, EPS Corporation

Conditions

Colorectal CancerLiver MetastasisLiver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancerlocally advanced pancreatic cancer

Phase 2

Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
CompletedNCT01836653
EPS CorporationLiver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
Start: 2013-05-31End: 2017-03-31Updated: 2017-08-02
PhaseII study of 5-FU/I-LV+L-OHP+CPT-11 combination chemotherapy(FOLFIRINOX) in 1st line treatment for locally advanced pancreatic cancer
Active, not recruitingJPRN-UMIN000013385
Osaka Medical College Hospitallocally advanced pancreatic cancer
Start: 2014-04-01Target: 45Updated: 2025-07-18

Unknown Phase

Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
CompletedNCT01834014
EPS CorporationColorectal Cancer, Liver Metastasis
Start: 2013-05-31End: 2017-03-31Updated: 2017-08-02

Related Papers

Effect size as a tool to identify subpopulations with improved clinical outcomes in metastatic colorectal cancer.
Journal of Clinical Oncology2020-02-01
Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).
2019-07-0939 citations
ATOM trial: a randomized phase II study of mFOLFOX6+Bmab vs. mFOLFOX6+Cmab for not-optimary resectable KRAS wt mCRC
Annals of Oncology2018-10-01
Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial
Annals of Oncology2018-10-01
A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).
Journal of Clinical Oncology2018-02-013 citations
The ATOM trial: A multicenter, randomized phase II study of modified FOLFOX6 plus bevacizumab and modified FOLFOX6 plus cetuximab for colorectal cancer with liver-limited metastases.
Journal of Clinical Oncology2016-02-011 citations